1. Market Research
  2. > Lung Infections - Pipeline Review, H2 2013

Lung Infections - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 60 pages

Lung Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Lung Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Infections. Lung Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Infections.
- A review of the Lung Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lung Infections - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lung Infections 7
Lung Infections Therapeutics under Development by Companies 9
Lung Infections Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Lung Infections Therapeutics - Products under Development by Companies 15
Lung Infections Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Lung Infections Therapeutics Development 17
Targeted Genetics Corporation 17
Bayer AG 18
Insmed Incorporated 19
Creative Antibiotics Sweden AB 20
Destiny Pharma Ltd. 21
Lung Infections - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
amikacin - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ciprofloxacin - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
amikacin liposomal - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
amikacin liposomal - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
BioPhage-PR - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
XF-70 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
INP-11252 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Cystic Fibrosis Phage - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Drug For Staphyloccal enterotoxin B And Toxic Shock Syndrome Toxin-1 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Lung Infections Therapeutics - Drug Profile Updates 40
Lung Infections Therapeutics - Discontinued Products 52
Lung Infections Therapeutics - Dormant Products 53
Lung Infections - Product Development Milestones 54
Featured News and Press Releases 54
May 14, 2013: Insmed Receives Key Composition Of Matter Patent Allowance For ARIKACE In Europe 54
Apr 17, 2013: KaloBios Pharma To Present Data On KB001-A At BIO 2013 International Convention 54
Mar 28, 2013: Insmed's Arikace Receives Orphan Drug Designation For Treating Infections Caused By Non- tuberculous Mycobacteria 55
Aug 02, 2012: Insmed Receives Second Composition Of Matter Patent For ARIKACE 55
Jun 27, 2012: Insmed Doses First Patient In TARGET-NTM Phase II Clinical Trial Of ARIKACE in Patients With Non-Tuberculous Mycobacteria Lung Disease 55
May 23, 2012: Insmed Begins Screening Patients For TARGET-NTM US Clinical Trial Of ARIKACE In Patients With Non-Tuberculous Mycobacterial Lung Disease 56
May 07, 2012: Insmed Announces Lifting Of Clinical Hold By FDA On ARIKACE In Cystic Fibrosis Patients With Pseudomonas Lung Infections 57
Sep 15, 2011: Nabriva Therapeutics Presents Extended Phase II Results For Pleuromutilin Antibiotic BC-3781 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables

Number of Products Under Development for Lung Infections, H2 2013 7
Products under Development for Lung Infections - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Targeted Genetics Corporation, H2 2013 17
Bayer AG, H2 2013 18
Insmed Incorporated, H2 2013 19
Creative Antibiotics Sweden AB, H2 2013 20
Destiny Pharma Ltd., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 26
Lung Infections Therapeutics - Drug Profile Updates 40
Lung Infections Therapeutics - Discontinued Products 52
Lung Infections Therapeutics - Dormant Products 53

List of Figures

Number of Products under Development for Lung Infections, H2 2013 7
Products under Development for Lung Infections - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 22
Assessment by Route of Administration, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Molecule Type, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.